 Approximately 52 investigative site globally are planned to participate in this study. An estimated 300 subjects with poorly controlled T2DM and moderate renal impairment will be randomly assigned to receive bexagliflozin tablets, 20 mg, or placebo in equal ratio for 24 weeks. 